Log on / register
Feedback | Support | My details
Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.
Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE
Trials 2007, 8:8
[Full text] [PubMed] [Related articles]


No citations for this article were found in PubMed Central.


You can also check ISI Web of Science for additional citations (subscription required)
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.